Eventide Asset Management - Q2 2021 holdings

$7.44 Billion is the total value of Eventide Asset Management's 152 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 23.1% .

 Value Shares↓ Weighting
FIVN BuyFIVE9 INC$216,495,000
+17.5%
1,180,515
+0.2%
2.91%
+6.5%
TTD BuyTHE TRADE DESK INC$213,237,000
+19.3%
2,756,430
+904.8%
2.86%
+8.1%
DT BuyDYNATRACE INC$159,505,000
+23.5%
2,730,308
+2.0%
2.14%
+12.0%
MTD BuyMETTLER TOLEDO INTERNATIONAL$155,158,000
+30.3%
112,000
+8.7%
2.08%
+18.1%
TWLO BuyTWILIO INCcl a$155,098,000
+16.1%
393,490
+0.4%
2.08%
+5.2%
ROP BuyROPER TECHNOLOGIES INC$146,890,000
+17.2%
312,400
+0.5%
1.97%
+6.2%
HUBS BuyHUBSPOT INC$138,651,000
+28.8%
237,937
+0.4%
1.86%
+16.8%
GNRC BuyGENERAC HLDGS INC$131,104,000
+74.7%
315,800
+37.8%
1.76%
+58.4%
FVRR BuyFIVERR INTL LTD$130,935,000
+13.4%
539,962
+1.6%
1.76%
+2.8%
TT BuyTRANE TECHNOLOGIES PLC$116,653,000
+13.5%
633,500
+2.0%
1.57%
+2.9%
POOL BuyPOOL CORP$115,491,000
+33.7%
251,800
+0.6%
1.55%
+21.2%
ODFL BuyOLD DOMINION FREIGHT LINE IN$112,230,000
+23.1%
442,200
+16.6%
1.51%
+11.6%
ZYME BuyZYMEWORKS INC$111,033,000
+151.5%
3,200,728
+129.0%
1.49%
+128.1%
CTAS BuyCINTAS CORP$110,627,000
+32.7%
289,600
+18.6%
1.49%
+20.3%
W BuyWAYFAIR INCcl a$105,309,000
+35.8%
333,562
+35.4%
1.42%
+23.2%
ARGX BuyARGENX SEsponsored adr$100,256,000
+70.1%
333,000
+55.6%
1.35%
+54.3%
BuyTRILLIUM THERAPEUTICS INC$92,247,000
+12.1%
9,510,000
+24.2%
1.24%
+1.6%
SPT BuySPROUT SOCIAL INC$90,486,000
+55.0%
1,011,920
+0.1%
1.22%
+40.6%
RNG BuyRINGCENTRAL INCcl a$87,932,000
+33.5%
302,608
+36.9%
1.18%
+21.0%
ENTG BuyENTEGRIS INC$80,127,000
+16.3%
651,599
+5.8%
1.08%
+5.4%
CLDX BuyCELLDEX THERAPEUTICS INC NEW$70,522,000
+66.0%
2,108,908
+2.3%
0.95%
+50.3%
PRAX BuyPRAXIS PRECISION MEDICINES I$67,727,000
-38.1%
3,787,053
+7.8%
0.91%
-43.9%
COLL BuyCOLLEGIUM PHARMACEUTICAL INC$62,164,000
+8.0%
2,629,593
+8.3%
0.84%
-2.1%
PANW BuyPALO ALTO NETWORKS INC$55,411,000
+15.3%
149,337
+0.1%
0.74%
+4.5%
ANNX BuyANNEXON INC$53,332,000
-2.5%
2,409,166
+20.2%
0.72%
-11.7%
SHLS BuySHOALS TECHNOLOGIES GROUP INcl a$51,385,000
+276.3%
1,447,460
+268.7%
0.69%
+241.6%
DDOG BuyDATADOG INC$50,490,000
+28.7%
485,104
+3.0%
0.68%
+16.5%
SMAR BuySMARTSHEET INC$50,344,000
+80.2%
696,131
+59.3%
0.68%
+63.3%
MAX BuyMEDIAALPHA INCcl a$50,125,000
+36.8%
1,190,612
+15.1%
0.67%
+23.9%
TPTX BuyTURNING POINT THERAPEUTICS I$45,096,000
-5.6%
578,000
+14.5%
0.61%
-14.4%
NCNO NewNCINO INC$39,697,000662,500
+100.0%
0.53%
CGEM BuyCULLINAN ONCOLOGY INC$36,155,000
-26.3%
1,440,145
+18.8%
0.49%
-33.1%
IMVT BuyIMMUNOVANT INC$35,631,000
-10.2%
3,370,994
+36.3%
0.48%
-18.5%
BCYC BuyBICYCLE THERAPEUTICS PLCsponsored ads$35,323,000
+187.1%
1,163,471
+182.5%
0.47%
+160.4%
ALLK BuyALLAKOS INC$34,233,000
-5.9%
401,000
+26.5%
0.46%
-14.7%
MDB BuyMONGODB INCcl a$32,304,000
+35.8%
89,355
+0.4%
0.43%
+22.9%
ADCT BuyADC THERAPEUTICS SA$31,948,000
+43.1%
1,311,990
+43.4%
0.43%
+29.6%
MPWR BuyMONOLITHIC PWR SYS INC$28,927,000
+10.4%
77,459
+4.4%
0.39%
+0.3%
SWKS BuySKYWORKS SOLUTIONS INC$28,388,000
+4.9%
148,047
+0.3%
0.38%
-5.0%
COMP NewCOMPASS INCcl a added$26,569,0002,022,031
+100.0%
0.36%
VECT NewVECTIVBIO HLDG AG$26,592,0002,341,427
+100.0%
0.36%
ALXO BuyALX ONCOLOGY HLDGS INC$24,056,000
+262.5%
439,950
+388.8%
0.32%
+229.6%
CRDF BuyCARDIFF ONCOLOGY INC$23,779,000
+44.0%
3,575,834
+100.5%
0.32%
+30.2%
TALS NewTALARIS THERAPEUTICS INC$22,411,0001,561,092
+100.0%
0.30%
A BuyAGILENT TECHNOLOGIES INC$22,423,000
+42.6%
151,700
+22.6%
0.30%
+29.2%
BFLY BuyBUTTERFLY NETWORK INC$19,765,000
+5.0%
1,365,000
+22.1%
0.27%
-4.7%
CCXI BuyCHEMOCENTRYX INC$18,786,000
-34.5%
1,403,000
+150.5%
0.25%
-40.7%
STE BuySTERIS PLC$18,299,000
+42.1%
88,700
+31.2%
0.25%
+28.8%
NVT NewNVENT ELECTRIC PLC$17,510,000560,500
+100.0%
0.24%
CIEN BuyCIENA CORP$17,361,000
+10.1%
305,175
+5.9%
0.23%
-0.4%
PLD BuyPROLOGIS INC.$16,519,000
+26.7%
138,200
+12.3%
0.22%
+15.0%
ORIC BuyORIC PHARMACEUTICALS INC$15,513,000
+47.3%
876,948
+103.9%
0.21%
+33.3%
BuyPALO ALTO NETWORKS INCnote 0.750% 7/0$14,388,000
+83.2%
9,855,000
+66.2%
0.19%
+66.4%
EQIX NewEQUINIX INC$14,200,00017,693
+100.0%
0.19%
PNR BuyPENTAIR PLC$14,254,000
+28.0%
211,200
+18.2%
0.19%
+15.8%
KLAC BuyKLA CORP$13,422,000
+13.5%
41,398
+15.6%
0.18%
+2.9%
SNPS BuySYNOPSYS INC$11,240,000
+62.3%
40,757
+45.8%
0.15%
+46.6%
SBAC BuySBA COMMUNICATIONS CORP NEWcl a$11,027,000
+74.5%
34,600
+52.0%
0.15%
+57.4%
BuyEXACT SCIENCES CORPnote 0.375% 3/0$10,296,000
+278.5%
8,295,000
+295.0%
0.14%
+245.0%
IEX BuyIDEX CORP$10,056,000
+27.4%
45,700
+21.2%
0.14%
+15.4%
PHVS BuyPHARVARIS N V$9,840,000
-29.9%
541,563
+8.3%
0.13%
-36.5%
ELS BuyEQUITY LIFESTYLE PPTYS INC$9,452,000
+55.8%
127,200
+33.5%
0.13%
+41.1%
AESC NewAES CORPunit 99/99/9999$8,950,00083,200
+100.0%
0.12%
BOLT BuyBOLT BIOTHERAPEUTICS INC$8,256,000
-22.3%
534,000
+65.4%
0.11%
-29.3%
VFC BuyV F CORP$7,794,000
+19.5%
95,000
+16.4%
0.10%
+8.2%
AWK BuyAMERICAN WTR WKS CO INC NEW$7,537,000
+16.6%
48,900
+13.5%
0.10%
+5.2%
MAAC NewMONTES ARCHIMEDES ACQUISITIO$6,923,000700,000
+100.0%
0.09%
AQNU NewALGONQUIN PWR UTILS CORPunit 99/99/9999 added$6,371,000128,300
+100.0%
0.09%
KBH NewKB HOME$6,426,000157,800
+100.0%
0.09%
ZTS BuyZOETIS INCcl a$6,113,000
+35.7%
32,800
+14.7%
0.08%
+22.4%
SYY BuySYSCO CORP$6,002,000
+2.5%
77,200
+3.8%
0.08%
-6.9%
NDAQ BuyNASDAQ INC$5,608,000
+41.9%
31,900
+19.0%
0.08%
+27.1%
LOB NewLIVE OAK BANCSHARES INC$3,699,00062,700
+100.0%
0.05%
SHW BuySHERWIN WILLIAMS CO$3,269,000
+58.2%
12,000
+328.6%
0.04%
+41.9%
SLAB BuySILICON LABORATORIES INC$2,933,000
+67.2%
19,137
+53.9%
0.04%
+50.0%
OM BuyOUTSET MED INC$2,867,000
+45.5%
57,357
+58.3%
0.04%
+34.5%
TMDX NewTRANSMEDICS GROUP INC$2,567,00077,364
+100.0%
0.03%
XMTR NewXOMETRY INC$1,311,00015,000
+100.0%
0.02%
AYX NewALTERYX INC$1,100,00011,000
+100.0%
0.02%
LMND NewLEMONADE INC$480,0006,000
+100.0%
0.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q2 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings